Company intelligence / Profile preview

Beijing Apollo Venus Biomedical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Licensed Tocagen's Toca 511 & Toca FC, a cancer-selective gene therapy regimen, for development and commercialization in greater China; main clinical result focus is ongoing pivotal Phase 3 (Toca 5) trial for recurrent HGG.

Therapeutic areas: Oncology
Modalities: Gene therapySmall moleculeImmunotherapy
Industry: Biotech

Partnerships

Tocagen Inc. (exclusive licensing agreement for Toca 511 & Toca FC)

Beyond the preview

Go deeper on Beijing Apollo Venus Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Apollo Venus Biomedical Technology.

Explore the full profile